RESEARCH ARTICLE


Early Postoperative Effect of Ripasudil Hydrochloride After Trabeculectomy on Secondary Glaucoma: A Randomized Controlled Trial



Tatsuya Mimura1, 2, *, Hidetaka Noma3, Yuji Inoue1, Makoto Kawashima1, Kazuma Kitsu1, Atsushi Mizota1
1 Department of Ophthalmology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.
2 Department of Ophthalmology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan
3 Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163 Tate, Hachioji-shi, Tokyo, 193-0998 Japan


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 229
Abstract HTML Views: 135
PDF Downloads: 187
ePub Downloads: 58
Total Views/Downloads: 609
Unique Statistics:

Full-Text HTML Views: 156
Abstract HTML Views: 102
PDF Downloads: 116
ePub Downloads: 50
Total Views/Downloads: 424



Creative Commons License
© 2022 Mimura et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Ophthalmology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605 Japan; Tel: +81-3-3964-1211; Fax: +81-3-3964-1402; E-mail: mimurat-tky@umin.ac.jp


Abstract

Purpose:

To evaluate the effect of Rho-associated kinase inhibitor (ripasudil hydrochloride hydrate; ripasudil) eye drops on postoperative intraocular pressure (IOP) after trabeculectomy in eyes with uveitic glaucoma.

Design:

This was a prospective, observational, controlled, and randomized study.

Methods:

Sixteen eyes of 16 patients with uveitic glaucoma who underwent trabeculectomy without mitomycin C were randomly treated without ripasudil (8 eyes) and with ripasudil (8 eyes). Postoperative IOP and surgical outcomes 3 months after surgery were compared between the two groups.

Results:

No patient discontinued treatment due to the lack of efficacy or adverse effects of ripasudil during the 3-month study period in the ripasudil group. The mean IOP (mmHg) in the control and ripasudil groups were 42.5 ± 9.8 mmHg /43.9 ± 11.7 mmHg (p = 0.82) at baseline, 14.3 ± 4.9 mmHg /9.0 ± 3.7 mmHg (p = 0.04) at 1 week, 16.3 ± 4.2 mmHg /10.6 ± 3.0 mmHg (p = 0.01) at 1 month, and 16.0 ± 3.4 mmHg /12.5 ± 2.3 mmHg (p = 0.04) at 3 months. The number of laser suture lysis procedures (2.0 ± 0.5 vs 0.4 ± 0.7), the rate of bleb revision by needling (50.0% vs 0.0%), and the mean number of antiglaucoma medications (1.6 ± 1.5 vs. 0.1 ± 0.3) after trabeculectomy were higher in the control group than in the ripasudil group (all p < 0.05). A multivariate analysis showed that the IOP reduction rate at 3 months after surgery was associated with the use of ripasudil and baseline IOP (all p < 0.05).

Conclusion:

This study demonstrated the therapeutic efficacy, safety, and tolerability of ripasudil for 3 months postoperatively. Ripasudil may effectively reduce postoperative IOP and increase the success rate of trabeculectomy in patients with uveitic glaucoma.

Keywords: Intraocular pressure, Ripasudil, Trabeculectomy, Uveitic glaucoma, Eye drops, Hydrochloride hydrate.